Home / Market News / $WIND
fiscal.ai Corporate Catalyst Impact 60/100 ● neutral

UBS Investment Bank Acts as Joint Book-Running Manager for Windward Bio Group AG IPO

Nov 13, 2026, 2:03 PM UTC · Primary ticker $WIND

Windward Bio Group AG announced the pricing of its IPO at $17.00 per share, with UBS Investment Bank acting as a joint book-running manager. This event marks the company's public market debut, providing it with capital for future operations and offering investors a new biotechnology stock.

Windward Bio Group AG has priced its initial public offering at $17.00 per share, selling 10,294,117 common shares. This is a significant event for Windward Bio as it transitions from a private to a public company, gaining access to capital markets to fund its clinical-stage biotechnology operations. For UBS Investment Bank, its role as a joint book-running manager is a routine business activity, generating fees but having minimal direct impact on its stock. Short-term, the IPO creates a new trading opportunity for investors interested in the biotech sector. Long-term implications depend on Windward Bio's clinical trial success and market adoption of its products. The key opportunity for traders is to evaluate Windward Bio's prospects post-IPO.

$WIND neutral IPO pricing announced
$UBS neutral Participating as joint book-runner
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.